CD8A and neoplasm: These polyclonal CD8+ and CD4+ antitumor T-cell responses raised against tumor neoantigens and/or TAAs would be beneficial in reducing tumor escape variants through the loss of single or multiple antigens in the tumor cell [195, 196, 197].